BridgeMD
Medical therapy after shock wave lithotripsy
EU CTIS ID: 2024-510792-38-01
What this study is testing
We would like to evaluate the effect of combined alpha-blocker (Tamsulosin) and diuretic (Furosemid) in respect to clearance of stone fragments following ESWL. Our hypothesis is that a supplement of Tamsulosin along with Furosemid will increase the effectivity of the treatment. It will thereby reduce the number of ESWL treatments and will reduce pain intensity and the need for pain medication after ESWL.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • Patients with kidney and proximally located ureteral stones with diameter < 2 cm • Patients >18 years • Able to understand the study procedures and willing to provide signed informed consent
You likely can't join if
- • Symptoms of urinary tract infection • Ureteral or nephrostomy stent placement prior to the intervention • Multiple stones • Renal functional deterioration • Severe hydronephrosis • Hypotension • Solitary kidney • Ectopic kidney and other anatomical anomalies • Patients have other disorders such as heart disease, kidney failure • Positive pregnancy test or fertile women without safety contraception • Allergy to one of the ingredients in the trial medicine
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.